Cargando…

New Liver MR Imaging Hallmarks for Small Hepatocellular Carcinoma Screening and Diagnosing in High-Risk Patients

OBJECTIVE: Early detection and diagnosis of hepatocellular carcinoma (HCC) is essential for prognosis; however, the imaging hallmarks for tumor detection and diagnosis has remained the same for years despite the use of many new immerging imaging methods. This study aimed to evaluate the detection pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Feifei, Wei, Yi, Zhang, Tong, Jiang, Hanyu, Li, Qian, Yuan, Yuan, Yao, Shan, Ye, Zheng, Wan, Shang, Wei, Xiaocheng, Nie, Lisha, Tang, Hehan, Song, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959840/
https://www.ncbi.nlm.nih.gov/pubmed/35356206
http://dx.doi.org/10.3389/fonc.2022.812832
_version_ 1784677250417819648
author Gao, Feifei
Wei, Yi
Zhang, Tong
Jiang, Hanyu
Li, Qian
Yuan, Yuan
Yao, Shan
Ye, Zheng
Wan, Shang
Wei, Xiaocheng
Nie, Lisha
Tang, Hehan
Song, Bin
author_facet Gao, Feifei
Wei, Yi
Zhang, Tong
Jiang, Hanyu
Li, Qian
Yuan, Yuan
Yao, Shan
Ye, Zheng
Wan, Shang
Wei, Xiaocheng
Nie, Lisha
Tang, Hehan
Song, Bin
author_sort Gao, Feifei
collection PubMed
description OBJECTIVE: Early detection and diagnosis of hepatocellular carcinoma (HCC) is essential for prognosis; however, the imaging hallmarks for tumor detection and diagnosis has remained the same for years despite the use of many new immerging imaging methods. This study aimed to evaluate the detection performance of hepatic nodules in high risk patients using either hepatobiliary specific contrast (HBSC) agent or extracellular contrast agent (ECA), and further to compare the diagnostic performances for hepatocellular carcinoma (HCC) using different diagnostic criteria with the histopathological results as reference standard. METHODS: This prospective study included 247 nodules in 222 patients (mean age, 53.32 ± 10.84 years; range, 22–79 years). The detection performance and imaging features of each nodule were evaluated in all MR sequences by three experienced abdominal radiologists. The detection performance of each nodule on all MR sequences were compared and further the diagnostic performance of various diagnostic criteria were evaluated. RESULTS: For those patients who underwent ECA-MRI, the conventional imaging hallmark of “AP + PVP and/or DP” was recommended, as 60.19% diagnostic sensitivity, 80.95% specificity and 100% lesion detection rate. Additionally, for those patients who underwent HBSC-MRI, the diagnostic criteria of “DWI + HBP” was recommended. This diagnostic criteria demonstrated, both in all tumor size and for nodules ≤2 cm, higher sensitivity (93.07 and 90.16%, all p <0.05, respectively) and slightly lower specificity (64.71 and 87.50%, all p >0.05, respectively) than that of the European Association for the Study of the Liver (EASL) criteria. CONCLUSIONS: Different abbreviated MR protocols were recommended for patients using either ECA or HBSC. These provided imaging settings demonstrated high lesion detection rate and diagnostic performance for HCC.
format Online
Article
Text
id pubmed-8959840
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89598402022-03-29 New Liver MR Imaging Hallmarks for Small Hepatocellular Carcinoma Screening and Diagnosing in High-Risk Patients Gao, Feifei Wei, Yi Zhang, Tong Jiang, Hanyu Li, Qian Yuan, Yuan Yao, Shan Ye, Zheng Wan, Shang Wei, Xiaocheng Nie, Lisha Tang, Hehan Song, Bin Front Oncol Oncology OBJECTIVE: Early detection and diagnosis of hepatocellular carcinoma (HCC) is essential for prognosis; however, the imaging hallmarks for tumor detection and diagnosis has remained the same for years despite the use of many new immerging imaging methods. This study aimed to evaluate the detection performance of hepatic nodules in high risk patients using either hepatobiliary specific contrast (HBSC) agent or extracellular contrast agent (ECA), and further to compare the diagnostic performances for hepatocellular carcinoma (HCC) using different diagnostic criteria with the histopathological results as reference standard. METHODS: This prospective study included 247 nodules in 222 patients (mean age, 53.32 ± 10.84 years; range, 22–79 years). The detection performance and imaging features of each nodule were evaluated in all MR sequences by three experienced abdominal radiologists. The detection performance of each nodule on all MR sequences were compared and further the diagnostic performance of various diagnostic criteria were evaluated. RESULTS: For those patients who underwent ECA-MRI, the conventional imaging hallmark of “AP + PVP and/or DP” was recommended, as 60.19% diagnostic sensitivity, 80.95% specificity and 100% lesion detection rate. Additionally, for those patients who underwent HBSC-MRI, the diagnostic criteria of “DWI + HBP” was recommended. This diagnostic criteria demonstrated, both in all tumor size and for nodules ≤2 cm, higher sensitivity (93.07 and 90.16%, all p <0.05, respectively) and slightly lower specificity (64.71 and 87.50%, all p >0.05, respectively) than that of the European Association for the Study of the Liver (EASL) criteria. CONCLUSIONS: Different abbreviated MR protocols were recommended for patients using either ECA or HBSC. These provided imaging settings demonstrated high lesion detection rate and diagnostic performance for HCC. Frontiers Media S.A. 2022-03-09 /pmc/articles/PMC8959840/ /pubmed/35356206 http://dx.doi.org/10.3389/fonc.2022.812832 Text en Copyright © 2022 Gao, Wei, Zhang, Jiang, Li, Yuan, Yao, Ye, Wan, Wei, Nie, Tang and Song https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Gao, Feifei
Wei, Yi
Zhang, Tong
Jiang, Hanyu
Li, Qian
Yuan, Yuan
Yao, Shan
Ye, Zheng
Wan, Shang
Wei, Xiaocheng
Nie, Lisha
Tang, Hehan
Song, Bin
New Liver MR Imaging Hallmarks for Small Hepatocellular Carcinoma Screening and Diagnosing in High-Risk Patients
title New Liver MR Imaging Hallmarks for Small Hepatocellular Carcinoma Screening and Diagnosing in High-Risk Patients
title_full New Liver MR Imaging Hallmarks for Small Hepatocellular Carcinoma Screening and Diagnosing in High-Risk Patients
title_fullStr New Liver MR Imaging Hallmarks for Small Hepatocellular Carcinoma Screening and Diagnosing in High-Risk Patients
title_full_unstemmed New Liver MR Imaging Hallmarks for Small Hepatocellular Carcinoma Screening and Diagnosing in High-Risk Patients
title_short New Liver MR Imaging Hallmarks for Small Hepatocellular Carcinoma Screening and Diagnosing in High-Risk Patients
title_sort new liver mr imaging hallmarks for small hepatocellular carcinoma screening and diagnosing in high-risk patients
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959840/
https://www.ncbi.nlm.nih.gov/pubmed/35356206
http://dx.doi.org/10.3389/fonc.2022.812832
work_keys_str_mv AT gaofeifei newlivermrimaginghallmarksforsmallhepatocellularcarcinomascreeninganddiagnosinginhighriskpatients
AT weiyi newlivermrimaginghallmarksforsmallhepatocellularcarcinomascreeninganddiagnosinginhighriskpatients
AT zhangtong newlivermrimaginghallmarksforsmallhepatocellularcarcinomascreeninganddiagnosinginhighriskpatients
AT jianghanyu newlivermrimaginghallmarksforsmallhepatocellularcarcinomascreeninganddiagnosinginhighriskpatients
AT liqian newlivermrimaginghallmarksforsmallhepatocellularcarcinomascreeninganddiagnosinginhighriskpatients
AT yuanyuan newlivermrimaginghallmarksforsmallhepatocellularcarcinomascreeninganddiagnosinginhighriskpatients
AT yaoshan newlivermrimaginghallmarksforsmallhepatocellularcarcinomascreeninganddiagnosinginhighriskpatients
AT yezheng newlivermrimaginghallmarksforsmallhepatocellularcarcinomascreeninganddiagnosinginhighriskpatients
AT wanshang newlivermrimaginghallmarksforsmallhepatocellularcarcinomascreeninganddiagnosinginhighriskpatients
AT weixiaocheng newlivermrimaginghallmarksforsmallhepatocellularcarcinomascreeninganddiagnosinginhighriskpatients
AT nielisha newlivermrimaginghallmarksforsmallhepatocellularcarcinomascreeninganddiagnosinginhighriskpatients
AT tanghehan newlivermrimaginghallmarksforsmallhepatocellularcarcinomascreeninganddiagnosinginhighriskpatients
AT songbin newlivermrimaginghallmarksforsmallhepatocellularcarcinomascreeninganddiagnosinginhighriskpatients